Intigyne

Lactobacillus gasseri DSM 14869 and Lactobacillus rhamnosus DSM 14870, the active ingredients in Intigyne, are probiotic strains presented as a vaginal probiotic formulation for vaginal use. It supports the natural vaginal microbiota and may help maintain balance in women.

GNH USA supplies Intigyne as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Intigyne, a vaginal probiotic, is used to support the normal vaginal microbiome and address conditions related to microbial imbalance.

- Bacterial vaginosis: helps restore lactobacilli dominance and reduce recurrence. - Recurrent vulvovaginal candidiasis: may aid in maintaining a protective flora that limits yeast overgrowth. - Post‑antibiotic therapy: assists in re‑establishing healthy vaginal bacteria after systemic antibiotics.

Intigyne is generally well tolerated, but some users may experience mild adverse reactions.

Common Side Effects: - Vaginal irritation or burning sensation. - Increased vaginal discharge or change in consistency. - Mild itching or discomfort. - Transient odor change. - Local allergic reaction (redness, swelling).

Serious or Rare Side Effects: - Systemic infection (rare in immunocompromised patients). - Severe allergic reaction or anaphylaxis. - Persistent or worsening irritation despite discontinuation. - Unexplained fever or pelvic pain. - Rare cases of opportunistic infection.

Before using Intigyne, consider the following safety measures.

- Pregnancy: consult a healthcare provider before use. - Breastfeeding: discuss potential use with a physician. - Known allergy: avoid if hypersensitivity to Lactobacillus strains is documented. - Immunocompromised patients: use with caution and under medical supervision. - Concurrent intravaginal antibiotics: may reduce probiotic viability; coordinate timing with a clinician. - Store at ambient temperature: keep in the original packaging, protect from moisture and direct sunlight.

Intigyne may interact with certain intravaginal and systemic agents.

Major Interactions (Avoid): - Intravaginal antibiotics: can kill probiotic strains and diminish efficacy. - Antifungal vaginal treatments: may interfere with colonisation of beneficial lactobacilli.

Moderate Interactions (Monitor Closely): - Oral broad‑spectrum antibiotics: may alter gut flora but have limited impact on vaginal probiotic activity. - Hormonal contraceptives: no known direct interaction, but monitor for any changes in vaginal symptoms. - Vaginal douches or antiseptics: can disrupt probiotic colonisation. - Use of spermicidal gels: may affect bacterial balance; observe for irritation.